Romina Salpini

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3587009/romina-salpini-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60 28 19 940 h-index g-index citations papers 65 6.7 1,171 3.45 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
60	Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile Microbiology Spectrum, 2022, e0273221	8.9	6
59	Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B. <i>Gut</i> , 2021 , 70, 2337-2348	19.2	14
58	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. <i>Microbiology Spectrum</i> , 2021 , e0109621	8.9	9
57	An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression. <i>Microorganisms</i> , 2021 , 9,	4.9	1
56	Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment. <i>Methods</i> , 2021 ,	4.6	3
55	Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 396-412	5.1	6
54	Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers. <i>Scientific Reports</i> , 2021 , 11, 3965	4.9	1
53	HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort. <i>Microorganisms</i> , 2021 , 9,	4.9	2
52	Crucial Role of Central Nervous System as a Viral Anatomical Compartment for HIV-1 Infection <i>Microorganisms</i> , 2021 , 9,	4.9	1
51	Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1778-1786	5.1	6
50	A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro. <i>Viruses</i> , 2020 , 12,	6.2	4
49	Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. <i>Drug Resistance Updates</i> , 2020 , 53, 100721	23.2	44
48	Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers. <i>Microorganisms</i> , 2020 , 8,	4.9	3
47	Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis. <i>Life</i> , 2020 , 10,	3	6
46	Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels , hinder HBsAg secretion and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. <i>Emerging Microbes and Infections</i> , 2020 , 9, 928-939	18.9	3
45	New Markers in Monitoring the Reactivation of Hepatitis B Virus Infection in Immunocompromised Hosts. <i>Viruses</i> , 2019 , 11,	6.2	7
44	HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy. <i>Scientific Reports</i> , 2019 , 9, 11942	4.9	8

(2016-2019)

43	Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report. <i>Journal of Medical Case</i>	1.2	2
42	Reports, 2019 , 13, 299 Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. Sexually Transmitted Infections, 2019 , 95, 619-625	2.8	9
41	HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon. <i>BMC Infectious Diseases</i> , 2019 , 19, 246	4	6
40	A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 846-855	3.4	8
39	GS-17-The integration of Hepatitis B virus into human genome is a common event in the setting of HBeAg negative disease: Implications for the treatment and management of CHB. <i>Journal of Hepatology</i> , 2019 , 70, e83-e84	13.4	3
38	Establishment of a Seronegative Occult Infection With an Active Hepatitis B Virus Reservoir Enriched of Vaccine Escape Mutations in a Vaccinated Infant After Liver Transplantation. <i>Journal of Infectious Diseases</i> , 2019 , 220, 1935-1939	7	4
37	Different Patterns of HIV-1 Replication in MACROPHAGES is Led by Co-Receptor Usage. <i>Medicina</i> (Lithuania), 2019 , 55,	3.1	11
36	Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofy356	1	31
35	The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. <i>Clinical Microbiology and Infection</i> , 2019 , 25, 906.e1-906.e7	9.5	8
34	Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. <i>BMC Infectious Diseases</i> , 2018 , 18, 251	4	20
33	HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. <i>Viruses</i> , 2018 , 10,	6.2	3
32	High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance. <i>PLoS ONE</i> , 2018 , 13, e0195045	3.7	9
31	Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS Ampliprep/COBASTaqMan HBV test v2.0. <i>Medical Microbiology and Immunology</i> , 2017 , 206, 295-299	4	
30	Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal. <i>BMC Infectious Diseases</i> , 2017 , 17, 566	4	8
29	Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro. <i>Oncotarget</i> , 2017 , 8, 15704-15715	3.3	7
28	HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Crosssectional Design. <i>Current HIV Research</i> , 2017 , 15, 66-73	1.3	3
27	Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE). <i>Journal of Infectious Diseases</i> , 2016 , 213, 39-48	7	25
26	Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B. <i>Journal of Infectious Diseases</i> , 2016 , 213, 1897-905	7	33

25	Systematic review and meta-analysis of hepatitis C virus infection and HIV viral load: new insights into epidemiologic synergy. <i>Journal of the International AIDS Society</i> , 2016 , 19, 20944	5.4	3
24	High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians. <i>Current HIV Research</i> , 2016 , 14, 165-71	1.3	20
23	Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. <i>Clinical Microbiology and Infection</i> , 2016 , 22, 946.e1-946.e8	9.5	22
22	A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 1124.e1-4	9.5	3
21	Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. <i>Journal of Infection</i> , 2015 , 70, 288-98	18.9	9
20	Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. <i>Hepatology</i> , 2015 , 61, 823-33	11.2	87
19	Reliable timescale inference of HBV genotype A origin and phylodynamics. <i>Infection, Genetics and Evolution</i> , 2015 , 32, 361-9	4.5	18
18	Molecular analysis of hepatitis B virus in Bulgaria. <i>Journal of Medical Virology</i> , 2013 , 85, 49-54	19.7	11
17	Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen. <i>Journal of Infection</i> , 2013 , 67, 303-12	18.9	20
16	Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution. <i>Journal of General Virology</i> , 2013 , 94, 143-149	4.9	24
15	Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. <i>Journal of Medical Virology</i> , 2013 , 85, 996-1004	19.7	16
14	Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. <i>Journal of Infection</i> , 2012 , 65, 180-3	18.9	32
13	Characterization of drug resistance mutations in naWe and ART-treated patients infected with HIV-1 in Yaounde, Cameroon. <i>Journal of Medical Virology</i> , 2012 , 84, 721-7	19.7	29
12	Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. <i>Antiviral Research</i> , 2012 , 93, 86-93	10.8	58
11	Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 1285-93	1.6	16
10	HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. <i>PLoS ONE</i> , 2012 , 7, e39652	3.7	74
9	Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. <i>Digestive and Liver Disease</i> , 2011 , 43, 975-83	3.3	27
8	Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. <i>Pediatric Infectious Disease Journal</i> , 2011 , 30, 1062-8	3.4	36

LIST OF PUBLICATIONS

7	Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naWe to antiviral drugs. <i>Antiviral Research</i> , 2011 , 92, 382-5	10.8	18
6	Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. <i>Archives of Virology</i> , 2011 , 156, 1235-43	2.6	29
5	HIV-2 A-subtype gp125ct that ions and their association with CCR5 and CXCR4 tropism. <i>Archives of Virology</i> , 2011 , 156, 1943-51	2.6	4
4	Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. <i>Infection</i> , 2011 , 39, 367-70	5.8	1
3	Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in Italy. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 1173-82	1.6	20
2	Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia. Digestive and Liver Disease, 2010 , 42, 902-7	3.3	11
1	The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. <i>Journal of Hepatology</i> , 2009 , 50, 461-70	13.4	36